Ann: Preliminary Final Report for period to 31 December 2018, page-29

Also....

Impairment assessment of technology licence and goodwill
The value of the technology licence and goodwill from the Admedus Vaccines transaction were subject to impairment testing at 31 December 2018 with no impairment arising as the recoverable amount was in excess of the associated cash generating unit. The impairment test was performed by determining a value for the Admedus Vaccines’ assets based on the announced proposed funding arrangement with Star Bright Holding Ltd. Under the executed Memorandum of Understanding, Admedus will hold 29.1% of a new company which will own Admedus Vaccines, and Star Bright will contribute $18 million to the new company for 60% of the equity in this company.